Monographs: Pharmaceutical substances: Dolutegravir sodium (Dolutegravirum natricum)2022-01
Molecular formula. C20H18F2N3NaO5 Relative molecular mass. 441.37 Graphic formula
Chemical name. (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2-H -pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide sodium salt (IUPAC), 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, sodium salt (1:1), (4R,12aS) (CAS); CAS Reg. No. 1051375-19-9. Description. A white to pale yellow powder. Solubility. Slightly soluble in water R, and very slightly soluble in methanol R. Category. Antiretroviral (integrase strand-transfer inhibitor). Storage. Dolutegravir sodium should be kept in a tightly closed container and protected from light and moisture. Additional information. Dolutegravir sodium may exhibit polymorphism. Definition. Dolutegravir sodium contains not less than 97.0% and not more than 102.0% ("Assay", method A) or not less than 99.0% and not more than 101.0% ("Assay", method B) of C20H18F2N3NaO5, calculated with reference to the anhydrous substance. Identity tests Either tests A, E and F or tests B, C, E and F or tests D, E and F may be applied.
Heavy metals. Use 0.5 g for the preparation of the test solution as described under 2.2.3 Limit test for heavy metals, Procedure 5; determine the heavy metals content according to Method C; not more than 20 μg/g. Water. Determine, as described under 2.8 Determination of water by the Karl Fischer method, Method A, using 0.300 g of the substance and a mixture of 90 volumes of methanol R and 10 volumes of glacial acetic acid R as the solvent; the water content is not more than 10 mg/g. Impurity A (dolutegravir enantiomer), impurity B and G (dolutegravir diastereomers). Perform the test in subdued light and without any prolonged interruptions, using low-actinic glassware. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with cellulose tris (4-chloro-3-methylphenyl carbamate) (5 µm). As the mobile phase, use a mixture of 980 volumes of acetonitrile R, 40 volumes of water R and 2 volumes of phosphoric acid (~1440 g/L) TS. Operate at a flow rate of 1.5 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 258 nm. Maintain the column temperature at 25 °C. Prepare the following solutions using as the diluent a mixture of 50 volumes of acetonitrile R and 50 volumes of water R. For solution (1), dissolve 50.0 mg of the test substance in 50.0 mL. For solution (2), dilute 5.0 mL of solution (1) to 100.0 mL. Dilute 3.0 mL of this solution to 100.0 mL. For solution (3), dissolve 5 mg of the test substance in 1 mL acetonitrile R. Add 4.5 mL water R and 4.5 mL hydrochloric acid (~ 420 g/L) TS and boil the solution under a reflux for 1 hour. Cool the solution to room temperature and dilute 1 mL of it to 10 mL with a mixture of 6 volumes of water R and 4 volumes of acetonitrile R. For solution (4), dissolve 2 mg of dolutegravir impurity D RS in 5 mL of acetonitrile R. Dilute 1 mL of this solution to 10 mL. For solution (5), dilute 2 mg of dolutegravir impurity B RS in 5 mL of acetonitrile R. Dilute 1 mL of this solution to 10 mL. For solution (6), mix 1 mL of solution (4) with 1.0 mL of solution (5). Inject 15 µL of solutions (3) and (6). Record the chromatogram for about 45 minutes. Use the chromatogram obtained with solution (3) to identify the peak due to impurity H. The chromatogram usually shows two principal peaks: the peak due to dolutegravir and the peak due to impurity H. Impurity G will elute at the same retention time as impurity H. The impurities are eluted at the following relative retentions with reference to dolutegravir (retention time about 22 minutes): impurity H and impurity G: about 0.41; impurity A: about 0.72, impurity F: about 0.88; impurity D: about 1.27 and impurity B: about 1.39; impurity C: 1.62. The test is not valid unless, in the chromatogram obtained with solution (6), the resolution between the peaks due to impurity D and due to impurity B is at least 1.5. Inject 15 µL of solutions (1) and (2). In the chromatogram obtained with solution (1):
Related substances. Perform the test in subdued light and without any prolonged interruptions, using low-actinic glassware. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl and pentafluorophenyl groups (5 µm). Use the following conditions for gradient elution:
Operate at a flow rate of 1.0 mL per minute. As a detector, use an ultraviolet spectrophotometer set at a wavelength of 258 nm. Maintain the column temperature at 45 °C. Prepare the following solutions using as the diluent a mixture of 60 volumes of water R and 40 volumes of acetonitrile R. For solution (1), dissolve 35.0 mg of the test substance and dilute to 50.0 mL. For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3), dilute 5.0 mL of solution (2) to 50.0 mL. For solution (4), dilute 2 mg of dolutegravir impurity D RS in 5 mL of acetonitrile R. Dilute 1 mL of this solution to 10 mL. For solution (5), dissolve 5 mg of the test substance in 1 mL acetonitrile R. Add 4.5 mL water R and 4.5 mL hydrochloric acid (~ 420 g/L) TS and boil the solution under a reflux for 1 hour. Cool the solution to room temperature and dilute 1 mL of it to 10 mL with a mixture of 6 volumes of water R and 4 volumes of acetonitrile R. For solution (6), mix 1 mL of solution (4) with 1 mL of solution (5). Inject 10 µL each of solutions (1), (2), (3), (4), (5) and (6). Use the chromatogram obtained with solution (4) and the chromatogram supplied with dolutegravir impurity D RS to identify the peak due to impurity D. Use the chromatogram obtained with solution (5) to identify the peak due to impurity H (the chromatogram usually shows two principal peaks: the peak due to dolutegravir and the peak due to impurity H). The impurities, if present, are eluted at the following relative retentions with reference to dolutegravir (retention time about 30 minutes): impurity C about 0.66; impurity F about 0.70; impurity D about 0.74; impurity H about 0.78; impurity E about 0.89; impurity J about 1.75; impurity K about 1.77; impurity L about 2.10. The test is not valid unless, in the chromatogram obtained with solution (6), the resolution factor between the peaks due to impurity D and due to impurity H is at least 1.5. Also, the test is not valid unless, in the chromatogram obtained with solution (3), the peak due to dolutegravir is obtained with a signal-to-noise ratio of at least 20. In the chromatogram obtained with solution (1):
Assay. Perform the assay in subdued light and without any prolonged interruptions, using low-actinic glassware.
Impurities
A. (4S,12aR)-N -[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide (dolutegravir enantiomer) (synthesis-related impurity).
B. (4R,12aR)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide (dolutegravir diastereomer) (synthesis-related impurity).
C. (4R,12aS)-N-benzyl-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1', 2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (desfluoro dolutegravir) (synthesis-related impurity).
D. (4R,12aS)-N-[(2-fluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1', 2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (2-fluoro dolutegravir) (synthesis-related impurity).
E. (4R,12aS)-N-[(4-fluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (4-fluoro dolutegravir) (synthesis-related impurity).
F. (4R,12aS)-N-[(2,6-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (2,6-difluoro dolutegravir) (synthesis-related impurity).
G. (4S,12aS)-N-[(2,4-difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide; (dolutegravir diastereomer)(synthesis-related impurity).
H. N-[(2,4-difluorophenyl)methyl]-9-hydroxy-2-[(2R)-4-hydroxybutan-2-yl]-1,8-dioxo-2,8-dihydro-1H-pyrido[1,2-a]pyrazine-7-carboxamide (synthesis-related impurity, degradation product).
J. (4R,12aS)-N-[(2,4-difluorophenyl)methyl]-4-methyl-6,8-dioxo-7-(phenylmethoxy)-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide (synthesis-related impurity).
K. (3R)-3-(7-{[(2,4-difluorophenyl)methyl]carbamoyl}-9-hydroxy-1,8-dioxo-1,8-dihydro-2H-pyrido[1,2-a]pyrazin-2-yl)butyl [(2,4-difluorophenyl)methyl]carbamate (synthesis-related impurity).
L. 4R,12aS)-N-[(2,4-difluorophenyl)methyl]-7-{[(2,4-difluorophenyl)methyl]amino}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide (synthesis-related impurity). |